NCF International

Artificial Intelligence (AI) and Machine Learning (ML) are playing an increasingly central role in pharmaceutical manufacturing and control. A position paper published by IFPMA in March 2026 outlines both the opportunities and the challenges associated with their adoption across the sector

As agreed during the 115th meeting of EMA’s GMP/GDP Inspectors Working Group (GMDP IWG), EMA has launched a targeted revision of Annex 15 of the GMPs. The consultation period on the Concept Paper will remain open until 9 April 2026

Quantum mechanics allows us to obtain very accurate results in the study of molecules. Over the years, numerous computational methods have been developed that are capable of studying the system under examination with different approaches, always rigorously based on quantum theories

AI is increasingly reshaping the pharmaceutical industry, moving beyond experimental use cases to become a concrete component of regulatory decision-making and patient-facing processes. Its growing adoption is redefining how medicinal products are researched, developed, approved and monitored throughout their lifecycle